Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axogen Inc (NQ: AXGN )

6.855 +0.045 (+0.66%)
Streaming Delayed Price Updated: 2:58 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 207,870
Open 6.790
Bid (Size) 6.840 (5)
Ask (Size) 6.870 (9)
Prev. Close 6.810
Today's Range 6.590 - 6.950
52wk Range 3.450 - 10.83
Shares Outstanding 41,397,053
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Showcasing Axogen’s Dedication to Fueling Ohio’s Biotechnology Sector Growth 
From Axogen, Inc.
Via GlobeNewswire
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
From Axogen, Inc.
Via GlobeNewswire

Performance

YTD
-0.80%
-0.80%
1 Month
+12.56%
+12.56%
3 Month
-10.63%
-10.63%
6 Month
-4.13%
-4.13%
1 Year
-24.25%
-24.25%

More News

Read More
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
From Axogen, Inc.
Via GlobeNewswire
Axogen Earnings Preview
Via Benzinga
AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Axogen, Inc Reports First Quarter 2024 Financial Results
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
From Axogen, Inc.
Via GlobeNewswire
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
From Axogen, Inc.
Via GlobeNewswire
Earnings Scheduled For March 5, 2024
Via Benzinga
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
From Axogen, Inc.
Via GlobeNewswire
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
From Axogen, Inc.
Via GlobeNewswire
Crude Oil Rises Over 2%; Constellation Brands Posts Downbeat Sales
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Greenbrier Posts Upbeat Earnings, Joins Kura Sushi USA, AxoGen And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces Promotions on Research and Development Team
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces Transition of Finance Team Leadership
From Axogen, Inc.
Via GlobeNewswire
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Axogen, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.